AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
More info
